Thermo Fisher Scientific unveils next-generation innovations at ASMS 2026 to accelerate the path from drug discovery to new therapies
New mass spectrometry platforms, combined with AI-driven analytics and scalable proteomics solutions, help scientists turn complex biology into actionable insights across research and drug development
31 May 2026Industry news
Thermo Fisher Scientific Inc., will showcase the Thermo Scientific™ Orbitrap™ Tribrid™ Apex and Thermo Scientific™ Orbitrap™ Excedion™ mass spectrometers at the American Society for Mass Spectrometry (ASMS) 2026 annual conference in San Diego from May 31–June 4, highlighting how new mass spectrometry platforms, AI-driven analytics and scalable proteomics solutions help scientists turn complex biology into actionable insights across research and drug development.
As scientific discovery expands into more complex applications, from advanced proteomics and multiomics to biologics and genetic medicines, researchers and drug developers face increasing pressure to generate high-quality data earlier and make confident decisions faster.
Thermo Fisher’s latest innovations address these needs by combining high-performance instrumentation with AI-enabled software for scalable multiomics and biopharmaceutical solutions to expedite both discovery and development. Together, these capabilities help scientists identify and validate disease mechanisms more efficiently, advancing targeted treatments.
Advancing early discovery with greater depth and versatility
Building on the proven Thermo Scientific Orbitrap Tribrid Technology, the Thermo Scientific Orbitrap Tribrid Apex Mass Spectrometer enables researchers to study complex biology across multiomics, structural biology, biopharma characterization and small-molecule analysis on a single system.
With five times greater sensitivity, up to 100% sequence coverage in a single experiment and results up to four times faster than previous-generation instruments, the Orbitrap Tribrid Apex allows scientists to better understand challenging samples without requiring multiple systems. Researchers can uncover underlying disease mechanisms earlier and identify therapeutic targets sooner across conditions such as cancer and neurodegeneration.
Supporting more than 300 areas of research, the Orbitrap Tribrid Apex mass spectrometer helps translate these discoveries into faster progress across drug discovery and development.
Enabling more confident decisions in drug development
As discoveries progress closer to development, the challenge shifts from understanding biology to generating the robust data needed to meet regulatory requirements and advance medicines with confidence. The Thermo Scientific Orbitrap Excedion Mass Spectrometer is designed to help pharmaceutical scientists reduce risk in increasingly complex drug development pipelines.
As new modalities such as GLP-1 therapies, oligonucleotides and antibody-drug conjugates introduce greater analytical complexities, identifying and validating key molecular signals early is essential. With the ability to detect three to five times more compounds in complex samples, the Orbitrap Excedion mass spectrometer provides more complete, regulatory-ready data to support decisions around safety, efficacy and dosing.
By enabling earlier detection of low-abundance or previously undetectable molecules, the platform supports earlier identification of critical signals, helping reduce downstream risk, improve regulatory readiness and accelerate time to market.
Connecting discovery to population-scale insight
Together, these Orbitrap innovations are part of Thermo Fisher’s broader strategy to connect biological discovery with large-scale validation and real-world research. At ASMS 2026, the company is also showcasing its Olink® proteomics platform, which enables high-specificity protein analysis at population scale and complements Orbitrap-based discovery workflows.
This combined approach is already being applied in initiatives such as PRECISE, one of Asia’s most ambitious and diverse biobank programs to uncover biomarkers linked to aging and metabolic disease.
Recent software acquisitions, MSAID and Proteinaceous, strengthen Thermo Fisher’s proteomics ecosystem by adding AI, machine learning and proteoform analysis capabilities that help scientists interpret complex population-scale datasets faster and with greater confidence.
Instruments are for general lab use only. Not for diagnostic purposes.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Frequently asked questions
How will Thermo Fisher Scientific’s Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers showcased at ASMS 2026 advance proteomics, multiomics and drug development?
Thermo Fisher Scientific Inc. will showcase the Thermo Scientific Orbitrap Tribrid Apex and Thermo Scientific Orbitrap Excedion mass spectrometers at the American Society for Mass Spectrometry (ASMS) 2026 annual conference in San Diego from May 31–June 4, 2026.
These Orbitrap platforms are designed to help scientists turn complex biology into actionable insights across research and drug development by combining high-performance mass spectrometry with AI-driven analytics and scalable proteomics solutions.
The Orbitrap Tribrid Apex supports advanced proteomics, multiomics, structural biology, biopharma characterization and small-molecule analysis on a single system, while the Orbitrap Excedion is optimized to help pharmaceutical scientists reduce risk in complex drug development pipelines by generating more complete, regulatory-ready data.
What are the key performance advantages of the Thermo Scientific Orbitrap Tribrid Apex Mass Spectrometer for proteomics, multiomics and disease research?
The Thermo Scientific Orbitrap Tribrid Apex Mass Spectrometer builds on proven Orbitrap Tribrid Technology to enable deeper and more versatile biological analysis. It offers five times greater sensitivity, up to 100% sequence coverage in a single experiment and results up to four times faster than previous-generation instruments.
Supporting more than 300 areas of research, it allows scientists to study complex biology across multiomics, structural biology, biopharma characterization and small-molecule analysis on a single system. These capabilities help researchers uncover underlying disease mechanisms earlier and identify therapeutic targets sooner in areas such as cancer and neurodegeneration, translating discoveries into faster progress across drug discovery and development.
How does the Thermo Scientific Orbitrap Excedion Mass Spectrometer, together with Olink proteomics and AI-enabled software, support regulatory-ready data and population-scale biomarker discovery?
The Thermo Scientific Orbitrap Excedion Mass Spectrometer is designed to help pharmaceutical scientists make more confident decisions in drug development by providing robust, regulatory-ready data.
As new modalities such as GLP-1 therapies, oligonucleotides and antibody-drug conjugates increase analytical complexity, the Orbitrap Excedion can detect three to five times more compounds in complex samples, enabling earlier detection of low-abundance or previously undetectable molecules. This supports earlier identification of critical signals related to safety, efficacy and dosing, helping reduce downstream risk, improve regulatory readiness and accelerate time to market.
At ASMS 2026, Thermo Fisher is also showcasing its Olink proteomics platform, which delivers high-specificity protein analysis at population scale and complements Orbitrap-based discovery workflows. Together with recent software acquisitions MSAID and Proteinaceous, which add AI, machine learning and proteoform analysis capabilities, Thermo Fisher’s ecosystem helps scientists interpret complex population-scale datasets faster and connect biological discovery to large-scale validation and real-world research, as demonstrated in initiatives such as the PRECISE biobank program.